PMC:7279721 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":152,"end":160},"obj":"Body_part"},{"id":"T2","span":{"begin":583,"end":593},"obj":"Body_part"},{"id":"T3","span":{"begin":876,"end":891},"obj":"Body_part"},{"id":"T4","span":{"begin":926,"end":931},"obj":"Body_part"},{"id":"T5","span":{"begin":984,"end":992},"obj":"Body_part"},{"id":"T6","span":{"begin":1145,"end":1153},"obj":"Body_part"},{"id":"T7","span":{"begin":1284,"end":1294},"obj":"Body_part"},{"id":"T8","span":{"begin":1284,"end":1292},"obj":"Body_part"},{"id":"T9","span":{"begin":1441,"end":1451},"obj":"Body_part"},{"id":"T10","span":{"begin":1441,"end":1449},"obj":"Body_part"},{"id":"T11","span":{"begin":1665,"end":1673},"obj":"Body_part"},{"id":"T12","span":{"begin":1814,"end":1822},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62340"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma49893"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma62340"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma62340"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma62338"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":876,"end":891},"obj":"Body_part"},{"id":"T2","span":{"begin":885,"end":891},"obj":"Body_part"},{"id":"T3","span":{"begin":926,"end":931},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-PubTator","denotations":[{"id":"4","span":{"begin":46,"end":54},"obj":"Species"},{"id":"5","span":{"begin":25,"end":42},"obj":"Disease"},{"id":"6","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"7","span":{"begin":82,"end":91},"obj":"Disease"},{"id":"12","span":{"begin":218,"end":226},"obj":"Species"},{"id":"13","span":{"begin":117,"end":134},"obj":"Disease"},{"id":"14","span":{"begin":232,"end":256},"obj":"Disease"},{"id":"15","span":{"begin":258,"end":266},"obj":"Disease"},{"id":"18","span":{"begin":318,"end":335},"obj":"Disease"},{"id":"19","span":{"begin":417,"end":425},"obj":"Disease"},{"id":"22","span":{"begin":435,"end":443},"obj":"Species"},{"id":"23","span":{"begin":449,"end":457},"obj":"Disease"},{"id":"37","span":{"begin":832,"end":835},"obj":"Species"},{"id":"38","span":{"begin":963,"end":971},"obj":"Species"},{"id":"39","span":{"begin":1067,"end":1075},"obj":"Species"},{"id":"40","span":{"begin":1123,"end":1131},"obj":"Species"},{"id":"41","span":{"begin":837,"end":859},"obj":"Disease"},{"id":"42","span":{"begin":861,"end":864},"obj":"Disease"},{"id":"43","span":{"begin":876,"end":899},"obj":"Disease"},{"id":"44","span":{"begin":901,"end":920},"obj":"Disease"},{"id":"45","span":{"begin":926,"end":939},"obj":"Disease"},{"id":"46","span":{"begin":1017,"end":1029},"obj":"Disease"},{"id":"47","span":{"begin":1034,"end":1042},"obj":"Disease"},{"id":"48","span":{"begin":1260,"end":1277},"obj":"Disease"},{"id":"49","span":{"begin":1360,"end":1365},"obj":"Disease"},{"id":"61","span":{"begin":1621,"end":1629},"obj":"Species"},{"id":"62","span":{"begin":1727,"end":1735},"obj":"Species"},{"id":"63","span":{"begin":1792,"end":1800},"obj":"Species"},{"id":"64","span":{"begin":1839,"end":1847},"obj":"Species"},{"id":"65","span":{"begin":1584,"end":1601},"obj":"Disease"},{"id":"66","span":{"begin":1648,"end":1656},"obj":"Disease"},{"id":"67","span":{"begin":1741,"end":1744},"obj":"Disease"},{"id":"68","span":{"begin":1769,"end":1786},"obj":"Disease"},{"id":"69","span":{"begin":1809,"end":1812},"obj":"Disease"},{"id":"70","span":{"begin":1866,"end":1874},"obj":"Disease"},{"id":"71","span":{"begin":1909,"end":1918},"obj":"Disease"}],"attributes":[{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D006333"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D003920"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D003643"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D002318"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"MESH:C000657245"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Tax:9606"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:C000657245"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Tax:9606"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Tax:9606"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D002318"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"MESH:D009202"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:D009202"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Tax:9606"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:9606"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D009202"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D003324"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D006973"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:C000657245"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"MESH:C000657245"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D001281"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:9606"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D009202"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:C000657245"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"Tax:9606"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D003643"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D009202"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:D007239"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D002318"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D009202"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":36,"end":42},"obj":"Disease"},{"id":"T2","span":{"begin":73,"end":81},"obj":"Disease"},{"id":"T3","span":{"begin":82,"end":91},"obj":"Disease"},{"id":"T4","span":{"begin":128,"end":134},"obj":"Disease"},{"id":"T5","span":{"begin":232,"end":256},"obj":"Disease"},{"id":"T6","span":{"begin":258,"end":266},"obj":"Disease"},{"id":"T7","span":{"begin":329,"end":335},"obj":"Disease"},{"id":"T8","span":{"begin":417,"end":425},"obj":"Disease"},{"id":"T9","span":{"begin":449,"end":457},"obj":"Disease"},{"id":"T10","span":{"begin":837,"end":865},"obj":"Disease"},{"id":"T11","span":{"begin":876,"end":899},"obj":"Disease"},{"id":"T12","span":{"begin":885,"end":899},"obj":"Disease"},{"id":"T13","span":{"begin":901,"end":920},"obj":"Disease"},{"id":"T14","span":{"begin":926,"end":939},"obj":"Disease"},{"id":"T15","span":{"begin":1017,"end":1029},"obj":"Disease"},{"id":"T16","span":{"begin":1034,"end":1042},"obj":"Disease"},{"id":"T17","span":{"begin":1271,"end":1277},"obj":"Disease"},{"id":"T18","span":{"begin":1595,"end":1601},"obj":"Disease"},{"id":"T19","span":{"begin":1648,"end":1656},"obj":"Disease"},{"id":"T20","span":{"begin":1780,"end":1786},"obj":"Disease"},{"id":"T21","span":{"begin":1866,"end":1874},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0000473"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0004981"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":281,"end":291},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T2","span":{"begin":363,"end":364},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":885,"end":891},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T4","span":{"begin":885,"end":891},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T5","span":{"begin":926,"end":931},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T6","span":{"begin":926,"end":931},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T7","span":{"begin":926,"end":931},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T8","span":{"begin":926,"end":931},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T9","span":{"begin":1044,"end":1045},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":1055,"end":1058},"obj":"http://purl.obolibrary.org/obo/CLO_0001404"},{"id":"T11","span":{"begin":1118,"end":1120},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T12","span":{"begin":1313,"end":1316},"obj":"http://purl.obolibrary.org/obo/CLO_0001375"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":91},"obj":"Sentence"},{"id":"T2","span":{"begin":92,"end":102},"obj":"Sentence"},{"id":"T3","span":{"begin":103,"end":280},"obj":"Sentence"},{"id":"T4","span":{"begin":281,"end":291},"obj":"Sentence"},{"id":"T5","span":{"begin":292,"end":426},"obj":"Sentence"},{"id":"T6","span":{"begin":427,"end":434},"obj":"Sentence"},{"id":"T7","span":{"begin":435,"end":682},"obj":"Sentence"},{"id":"T8","span":{"begin":683,"end":781},"obj":"Sentence"},{"id":"T9","span":{"begin":782,"end":789},"obj":"Sentence"},{"id":"T10","span":{"begin":790,"end":836},"obj":"Sentence"},{"id":"T11","span":{"begin":837,"end":1043},"obj":"Sentence"},{"id":"T12","span":{"begin":1044,"end":1104},"obj":"Sentence"},{"id":"T13","span":{"begin":1105,"end":1169},"obj":"Sentence"},{"id":"T14","span":{"begin":1170,"end":1379},"obj":"Sentence"},{"id":"T15","span":{"begin":1380,"end":1571},"obj":"Sentence"},{"id":"T16","span":{"begin":1572,"end":1583},"obj":"Sentence"},{"id":"T17","span":{"begin":1584,"end":1726},"obj":"Sentence"},{"id":"T18","span":{"begin":1727,"end":1813},"obj":"Sentence"},{"id":"T19","span":{"begin":1814,"end":1919},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":837,"end":859},"obj":"Phenotype"},{"id":"T2","span":{"begin":901,"end":920},"obj":"Phenotype"},{"id":"T3","span":{"begin":926,"end":939},"obj":"Phenotype"},{"id":"T4","span":{"begin":1017,"end":1029},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0005110"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection\nBackground\nThe degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among US hospitalized patients with Coronavirus Disease 2019 (COVID-19) are unknown.\nObjectives\nTo describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.\nMethods\nPatients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value \u003c0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.\nResults\nThe median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were significantly associated with death (adjusted HR: 1.75, 95% CI 1.37-2.24; P\u003c0.001) while greater amounts (e.g. troponin I\u003e0.09 ng/dL, n=530, 19.4%) were significantly associated with higher risk (adjusted HR 3.03, 95% CI 2.42-3.80; P\u003c0.001).\nConclusions\nMyocardial injury is prevalent among patients hospitalized with COVID-19 however troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality."}